Treatment Information

Back

Lung Cancer treatment details. Immunotherapy.

Hospital Hermanos Ameijeiras, Ciudad Habana, Cuba.

Survival: monthsCountry:Cuba
Toxiciy Grade:2City/State/Province:Ciudad Habana
Treatments:ImmunotherapyHospital:Hospital Hermanos Ameijeiras
Drugs:Journal:Link
Date:Mar 2008

Description:

Patients: This phase II study involved 80 patients with advanced non-small-cell lung cancer. The median age was 55.5, ranging from 30 to 78 years of age. The majority (74%) were men. All had previously received a platinum-based chemotherapy, and almost half received a radiation treatment.

Treatment: Patients were either treated with a vaccine or received best supportive care. This vaccine is designed to cause patients immune system to attack cells that express the epidermal growth factor receptor.

Toxicity: No grade 3 or 4 toxicities were reported. Grade 1 and 2 toxicities included fever, chills, nausea, vomiting, tremor, headache, arthralgia, asthenia, pain at the injection site, and acneiform rash.

Results: The median overall survival of vaccinated patients was 6.47 months and 5.33 months for the control group. Among the vaccinated patients, those with a good immune response to the vaccine had a median overall survival of 11.7 months. Those that did not have a good immune response to the vaccine had a median overall survival of 3.6 months.

Correspondence: Dr. Elia Neninger Vinageras





Back